Bionano Genomics, Inc. (NASDAQ:BNGO) is expected to report third quarter earnings results, after market close, on Thursday 12th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.05 per share.
Looking ahead, the full year loss are expected at $ 0.37 per share on the revenues of $ 7.96 million.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 1.90 million ~ $ 2.30 million
Click Here For More Historical Outlooks Of Bionano Genomics, Inc.
Previous Quarter Performance
Bionano Genomics, Inc. reported loss for the second quarter of $ 0.09 per share, from the revenue of $ 1.18 million. The quarterly revenues reduced 45.87 percent compared with the same quarter last year. Wall street analysts are predicting, BNGO to report 2Q20 loss of $ 0.09 per share from revenue of $ 0.86 million. The top line results outshined analysts by $ 0.32 million or 37.21 percent.
Stock Performance
Shares of Bionano Genomics, Inc. traded up $ 0.03 or 6.59 percent on Wednesday, reaching $ 0.56 with volume of 3.17 million shares. Bionano Genomics, Inc. has traded high as $ 0.56 and has cracked $ 0.54 on the downward trend
The closing price of $ 0.56, representing a 112.00 % increase from the 52 week low of $ 0.25 and a 61.87 % decrease over the 52 week high of $ 1.39.
The company has a market capital of $ 80.99 million and is part of the Healthcare sector and Diagnostics & Research industry.
Conference Call
Bionano Genomics, Inc. will be hosting a conference call at 4:30 PM eastern time on 12th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, 877-407-0784 U.S. or 201-689-8560 Outside U.S., with passcode : 13712129 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.bionanogenomics.com
Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics.
